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The role of glycosylation in breast
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Glycosylation and its correlation to the formation of remote metastasis in breast cancer
had been an important scientific topic in the last 25 years. With the development of
new analytical techniques, new insights were gained on the mechanisms underlying
metastasis formation and the role of aberrant glycosylation within. Mucin-1 and Galectin
were recognized as key players in glycosylation. Interestingly, aberrant carbohydrate
structures seem to support the development of brain metastasis in breast cancer patients,
as changes in glycosylation structures facilitate an overcoming of blood–brain barrier.
Changes in the gene expression of glycosyltransferases are the leading cause for a
modification of carbohydrate chains, so that also altered gene expression plays a role for
glycosylation. In consequence, glycosylation and changes within can be useful for cancer
diagnosis, determination of tumor stage, and prognosis, but can as well be targets for
therapeutic strategies. Thus, further research on this topic would worthwhile for cancer
combating.
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GLYCOSYLATION IN BREAST CANCER
METASTASIS – PAST AND PRESENT
Almost 25 years ago, researchers found a correlation between altered glycosylation of primary breast
cancer cells and the formation of lymph node metastasis. Back then, changes in glycosylation
were measured by the binding of helix pomatia lectin (HPA) to cellular structures like alpha-N-
acetylgalactosamine residues, for example, the Thomsen-nouvelle (Tn) epitope or blood group A
antigen. A coherence between staining of paraffin embedded tissues with HPA and the development
of metastasis, especially in lymph nodes could be shown, while no association could be proved
with tumor size, histological grade, or patient age at time of diagnosis. HPA staining was regarded
as a predictor for long-term prognosis (1, 2). Another scientific approach was the analysis of
glycosylation via Datura stramonium agglutinin (DSA)-Sepharose column, in which was shown
that metastasized carcinomas contain two times more DSA-binding oligosaccharides than the
Abbreviations: Ag, antigen; ARM-1, adhesion-regulating molecule; CA15-3, cancer antigen; CD44, cluster of differentiation;
CEA, carcinoembryonic antigen; CTCs, circulating tumor cells; DSA, Datura stramonium agglutinin; DTCs, disseminated
tumor cells; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; EMMPRIN, extracellular metallo-
proteinase inhibitor; EMT, epithelial to mesenchymal transition; ER, estrogen receptor; FUT, fucosyltransferase; GCNT,
glucosaminyl (N-acetyl) transferase;HDL, high density lipoprotein;HPA, helix pomatia agglutinin;MDR,multidrug resistance
protein; MMP, matrix-metalloproteinase; RAGE, receptor of advanced glycosylation end products; RPN, ribophorin; T,
Thomsen–Friedenreich antigen; Tn, Thomsen-nouvelle antigen; TGF, transforming growth factor.
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normal mammary gland, while primary carcinomas contain an
intermediate amount (3). Only a few years later, the Tn and
Thomsen–Friedenreich (T) epitopes were recognized as autoim-
munogenic pancarcinoma antigens, playing a role in cell invasion
and metastasis (4). In 2000, CA15-3, a serum marker for breast
cancer, was also recognized to have functions in breast cancer
metastasis (5). In the following years, more and more modifi-
cations of glycosyl structures became known, having to do with
breast cancer metastasis, for example 2,6 sialylation, which also
contributes to altered cell adhesion (6).
After summarizing former research results, in the following
passage the most recent insights into glycosylation and its influ-
ence on breast cancer metastasis should be further illustrated.
In 2011, the correlation between circulating tumor cells (CTCs)
and glycosylation was investigated. Bi-, Tri-, and Tetraantennary-
sialyl-Lewis x epitopes were detected in blood samples of
metastatic breast cancer patients and healthy persons by high-
performance liquid chromatography and results were compared.
Glycan levels were found to be higher in breast cancer patients
with high CTC counts, than in samples in which only few CTCs
were detected and in healthy controls, so that they could be
regarded as a prognostic marker (7). Another important pathway
in breast cancer metastasis is the glucosaminyl (N-acetyl) trans-
ferase 2 (GCNT2)-pathway. The GCNT2 gene is overexpressed in
metastatic tumor samples, and an ectopic expression of this gene
provokes enhanced cell detachment from the extracellular matrix
(ECM), adhesion to endothelial cells, cell migration and invasion
in vitro, and lung metastases in in vivo model systems. GCNT2
is also involved in epithelial to mesenchymal transition (EMT),
changing the expression of E-cadherin at the protein level and it
is an effector in the TGF-beta signaling cascade. Therefore, in the
future it might also become an interesting therapeutical target (8).
Also, S100P, an EF-hand calcium-binding protein, was found to
be another mediator of breast cancer malignancy and metastasis
(9). There is also a difference in glycosylation in ER-positive and
ER-negative tumors. Genes, involved in the synthesis of sialyl-
Lewis x [sLe(x)] (FUT3, FUT4, ST3GAL6) are highly expressed in
ER-negative tumors. ER-positive tumors with high expression of
sLe(x) are correlatedwith bonemetastasis, so that, for using sLe(x)
as a tumor marker, the genetical surrounding has to be regarded
(10). In a mouse model, it could be shown that S100A7/psoriasin
is an important factor for breast tumorigenesis and metastasis by
activation of proinflammatory pathways (11). Another associa-
tion was found between diabetes mellitus and breast cancer, as
glycosylation and oxidation of HDL, which are found in diabetic
patients, lead to abnormal cell adhesion properties, in turn pro-
voking metastasis formation, especially in the lungs and in the
liver (12). In a further study, it was found that the actin-binding
protein cofilin, which is O-GlcNAcetylated, is localized at the
leading edge of lamellipodia, thereby playing an important role in
cell migration. A loss of glycosylation of cofilin destabilizes the
lamellipodia, impairing, or at least reducing metastatic potential
of cells (13). That gives hints toward the role post-translational
glycosylation is playing in tumor formation. Another rather recent
finding in the field of glycosylation came fromphyllodes tumors of
the breast, an aggressively growing type of breast cancer: the gene
expression of Axl and ST6GalNAcII was increased in malignant
tumors, whereas the expression of Axl seems to be dependent on
the expression of ST6GalNAcII. Their expression was correlated
to tumor grading and the development of remote metastasis (14).
And last but not least, also functional CD44 might be involved
in breast cancer metastasis, representing a ligand for E-selectin,
pointing again toward a role for CD44 in cell adhesion and
motility (15).
MOLECULES ASSOCIATED WITH
GLYCOSYLATION IN BREAST CANCER
Helix Pomatia Lectin
Helix pomatia lectin recognizes mostly alpha-N-
acetylgalactosamine residues, which are conferred to cells
by an abnormal expression and activity of glycosyltransferases.
The changes in glycosylation of cellular structures lead to an
increased invasive capacity of these cells, thereby opening roads
for the formation of remote metastasis, especially in local lymph
nodes. HPA binding can therefore be regarded as a prognostic
marker for clinical decisions like treatment strategies (16).
Recently, the binding partners of HPA were analyzed more
thoroughly. As major binding partners IgA1, complement factor
C3, von Willebrand factor, alpha-2-macroglobulin, and IgM were
identified. Hence, in the use of HPA in tumor characterization,
blood group antigens have to be taken in consideration, or more
in general, the genetical context of the patient has to be regarded,
before deciding on therapeutical means (17). It was verified
again by some glycotope expression analysis carried out in 2011
that HPA binding is a marker for metastasis (18). Furthermore,
proteins that were identified as binding partners of HPA even
give hints toward future outcome, as, for example, Integrin alpha
6 was the most abundant HPA glycoprotein in breast cancer cells
with high metastatic potential (19).
Mucin-1
Mucin-1, a large transmembrane protein, located on the apical
surface of human epithelial cells, has already early been recognized
as a carrier of aberrantO-glycosylation in tumor cells. The changes
in glycosylation are accompanied by exposure of the protein core,
which in term mediates the attachment of those cells to tissue
at different sites, which is an important step in the formation of
remote metastasis (20). This underglycosylation of MUC1 is also
associated with a higher grading and might serve as a diagnostic
marker (21). One protein, CIN85, was identified recently, which
associates with MUC1 in tumor cells. The complex formed of
these two proteins is a key mediator for cell migration and inva-
sion, thereby promoting metastasis formation (22). Furthermore,
it was found out that MUC1, MUC1-core, and TF are especially
expressed in mucinous tumors (as well in primary tumors as in
the corresponding metastases), while CA19-9, CA50, and CA242
seemed to be more characteristic for gastrointestinal tumors (23).
Galectins
Galectins are endogenous galactoside-binding lectins with con-
served features in the binding site. They are involved in cell
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adhesion and growth regulation.An increased binding of galectin-
1 and reduced expression of galectin-3 or a reduced bind-
ing of both seemed to correlate with lymph node metasta-
sis (24). Another correlation was found for galectin-3 and
gelatinase B [matrix-metalloproteinase-9 (MMP-9)]. Cancer-
associated isoforms of MMP-9 bound galectin-3 in a rather
reduced manner than natural MMP-9 did. The role of galectin-
3 is to bind laminin and MMP-9, thereby locating MMP-9 to
the ECM. If this binding is reduced in tumor cells and MMP-
9 is not bound to ECM, it cleaves ECM-proteins influencing
cell adhesion properties in respect to metastasis formation (25).
Another ligand for galectin-3 is cancer-associated MUC1. This
binding is mediated by the Thomsen–Friedenreich antigen (TF-
Ag), and it promotes cancer cell adhesion to the endothelium,
contributing in this way to metastasis formation (26, 27).
INFLUENCE OF GENE EXPRESSION ON
GLYCOSYLATION AND METASTASIS
There are, of course, some more genes and their gene products,
which play a role in metastasis formation in the context of gly-
cosylation. In 1999, the adhesion-regulating molecule-1 (ARM-
1) was identified by expression library screening from a murine
lymphoma cell line. This gene codes for a type I transmembrane
protein with O- and N-glycosylation sites, and shows increased
expression in metastatic breast cancer cell lines in comparison to
non-metastatic cells (28). Another gene/gene product involved in
breast cancer metastasis seems to be extracellular matrix metal-
loproteinase inducer (EMMPRIN), which stimulates peritumoral
fibroblasts to produce MMPs, which in turn contribute to tumor
invasion. EMMPRIN isoforms are differentially glycosylated with
Lewis x structures and could serve as therapeutic and diagnostic
target by predicting negative side effects (29). A completely differ-
ent mechanism is seen for Ribophorin II (RPN2). It is part of an
N-oligosaccharide transferase complex, which is responsible for
drug resistance in breast cancer cells. A lower expression of RPN2
results in a reduced glycosylation and delocalization of CD63. The
localization of the multidrug resistance protein (MDR1) is regu-
lated by CD63, which in turn plays a role in cancer malignancy by
drug resistance and cell invasion (30).
GLYCOSYLATION AND
BRAIN METASTASIS
Galectin-3 is also a famous molecule in tumor progression. Its
expression is negative in normal breast tissue, but is increased
in breast cancer and brain metastases (31). Nevertheless, for
the formation of metastases in the brain a rather sophisticated
cascade of molecules is necessary to pass the blood–brain bar-
rier. A specific mediator to overcome this barrier seems to be
ST6GALNAC5,which is not only expressed in the brain but also in
breast cancer cells, mediating the adhesion of cancer cells to brain
endothelial cells by changing glycosylation patterns (32). Another
glycosyltransferase, GALNT9, an initiator of O-glycosylation, also
seems to play a role in breast-to-brainmetastatic process, andmay
become a useful prognostic marker (33).
GLYCOSYLATION IN CANCER CONTROL
Breast Cancer Diagnosis
Alterations in glycosylation structures could serve as impor-
tant diagnostic markers. In 2005, the role of beta-1,6-branched
oligosaccharides, which are transferred to N-glycans by beta-
1,6-N-acteylglucosaminyltransferase V, was shown by Hander-
son et al. The appearance of those oligosaccharide structures
could be related to nodal metastasis, and are a predictor of
poor outcome, independent of tumor size, grading, or patient
age at primary diagnosis (34). Another marker for a poor clin-
ical outcome is the occurrence of disseminated tumor cells
(DTCs) in the bone marrow of breast cancer patients. DTCs
also have aberrant glycosylation motifs, and can be detected by
the presence of UDP-N-acetyl--galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 (ppGalNAc-T6)mRNA in bone
marrow aspirates by RT-PCR (35). Also, the receptor of advanced
glycosylation end products (RAGE) and its soluble form (sRAGE)
could be used in cancer diagnosis: patients with breast cancer at
high stages show lower sRAGE levels, and these low levels might
contribute to disease progression (36). After a digestion of the
glycan pool of a cell with a combination of sialidase and beta-
galactosidase, a digestion product was obtained in the form of a
monogalactosylated triantennary structure containing alpha 1,3-
linked fucose. This product was found twice as much in breast
cancer patients than in samples of a healthy control group and
even seems to be better biomarker than CA15-3 and CEA in
predicting disease progression and occurrence of remote metas-
tasis (37). Another marker predicting disease progression and a
tendency toward lymphnodemetastasis is glycodelin, an endome-
trially secreted glycoprotein, which exists in different glycosyla-
tion states (38). In a mouse model, the changes in N-linked gly-
cans during cancer progression were measured by matrix-assisted
laser desorption/ionization Fourier transform-ion cyclotronmass
spectrometry. The results were transferred to human serum sam-
ples, and an alteration in low-abundance high-mannose glycans
could be seen in breast cancer patients, especially an elevation
of a high-mannose type glycan was seen in mouse and human
breast cancer sera, suggesting an incompletion of the glycosylation
process (39). Another method for the analysis of glycosylation
might be the detection of antibodies produced by the immune
system against even minor changes in glycosylation structures.
The advantage of this method is the earlier detection of antibodies
in comparison to the antigen. Such a study was performed by Blixt
et al. to analyze changes in Mucin-1 O-glycosylation from serum
of breast cancer patients. Antibody levels were significantly higher
in sera of cancer patients than in healthy control samples. High
levels of core3MUC1 could even be correlated to a later onset of
metastasis, thereby representing a promising new tumor marker
(40). Another technique for the analysis of glycosylation is the
conduction of lectin microarrays and a lectin-binding signature
for breast cancermetastasis had already been described (41). Also,
ELISAs using HPA could serve in cancer diagnostics. In a rather
recent assay cadherin-5 glycosylation was thereby found to be
a marker for breast cancer recurrence with a specificity of 90%
(42). Mircoarray analysis of glycosylation-related genes in breast
cancer samples lead to an interesting finding: in luminal cancers
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N-glycosylation seemed to be more prominent, while in triple-
negative cancers O-glycosylation plays a more important role
in tumor progression, pointing toward a different effect of gly-
cosylation patterns (43). In further analyses using lectin his-
tochemistry and tissue microarrays, it was shown that lectin
binding correlates with parameters involved in tumor metastasis
and significantly shorter overall survival (OAS), so that it could
be concluded once more that glycosylation and the enzymes
involved in glycosylation processes play an important role in
cancer progression (44). Another example for those findings is
the enzyme fucosyltransferase IV (FUT IV), which is associated
with proliferation and metastasis of breast cancer and could serve
as a new biomarker in the diagnosis and prognosis of breast
cancer (45).
Glycosylation in Breast Cancer Therapy
Further research was done in order to use glycosylation of cellular
structures not only in cancer diagnosis and prognosis, but also
for therapeutical means (46). As early as 2001, a development
of anti-cancer vaccines on the basis of carbohydrate structures
was attempted. Some glycosyl structures are already known to
suppress metastasis and invasive potential, in some cases also
the mechanisms for suppression are known and some anti-cancer
vaccines were already reported. The great challenge in this field
is to develop vaccines that provide a similar effect to that of
tumor-associated carbohydrate antigens in respect to suppression
of tumor progression (47). Such a target for cancer therapy could
be the TF-Ag, which is expressed exclusively on the surface of
tumor cells and has influence on cell adhesion and thereby on
metastasis formation. Treatment of a mouse breast cancer model
with JAA-F11, a monoclonal antibody to TF-Ag already led to
reduced lung metastasis formation and improved prognosis. As
natural antibodies against TF are produced from the body, the risk
within such a vaccination for cancer patient is relatively small, so
that it could be a rather promising therapeutic target (48). In line
with TF, also antibodies against Tn seemed to have therapeutical
meanings: a monoclonal antibody to Tn (2154F12A4) selectively
recognized Tn and inhibited the adhesion of cancer cells to the
lymphatic endothelium, and could thus inhibit lymphatic metas-
tases (49). Another interesting fact was reported from Yuan et al.
(50): they could show that a defucosylation impaired rolling of
human breast cancer cells on a cell layer and increased simultane-
ously the flow speed of the tumor cells, so that it was concluded
that reduced fucosylation levels impaired interaction of tumor
cells with endothelial cells, modulating tumor progression and
thus being also a target for tumor therapy (50).
CONCLUSION
Glycosylation plays an important role in a number of processes
leading to breast cancer metastasis. A lot of research was already
done on this topic in the last 25 years, clarifying the role of some
glycosyltransferases, examining the function of altered glycosyla-
tion for cell adhesion and motility properties, ending up in the
analysis of different glycosylation patterns for metastasis forma-
tion. But still lots of work needs to be done to understand better
the mechanisms of metastasis formation and the involvement of
glycosylation within, to profit from this knowledge in terms of
cancer diagnosis and treatment options. Further research in this
field could open new roads in breast cancer diagnosis as certain
glycosylation pattern could possibly be related to clinical outcome
and could help to analyze, which changes happened in the tumor
cells. Emanating from this knowledge also cancer therapeutics
could profit from the analysis of glycosylation patterns. The exam-
ination of glycosylation patterns could lead to amore personalized
tumor therapy, in which side effects could be reduced while the
efficiency of a therapy is increased. Therefore, glycosylationmight
play an important role in cancer combating in the future.
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